A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma.
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2013
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Fluticasone furoate
- Indications Asthma
- Focus Adverse reactions; Pharmacogenomic; Registrational
- Sponsors GlaxoSmithKline
- 15 Feb 2013 Planned number of patients changed from 500 to 503 as reported by European Clinical Trials Database record.
- 19 Jul 2011 New trial record